Startups
Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
Overview
Total raised
$29.07M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Crealia | crealia.org |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Mar 20, 2017 | Funding round | $17.18M |
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 20, 2021 | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA SibnayalTM eligible for reimbursement by the French public health insurance systemASMR IV: Recognition of the contribution of... |
| Dec 20, 2021 | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA SibnayalTM eligible for reimbursement by the French public health insurance systemASMR IV: Recognition of the contribution of... |
| Dec 20, 2021 | Advicenne Announces Positive Opinion From the French Transparency Commission (HAS) for its Drug Sibnayal™ in dRTA | Regulatory News: Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces is has received a positive opinion fr... |
| Dec 7, 2021 | Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe | Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe First round of pricing negotiations completed in the United Kingdom TwinPharma and ExCEEd Orphan to commercialize Sibnayal™ in Benelux and Central an... |
| Sep 29, 2021 | Advicenne : September 29, 2021 - Advicenne Reports 2021 Half Year Financial Results | Advicenne Reports 2021 Half Year Financial Results Paris, France, 29 September 2021 - 7:00AM (CEST) - Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for thos... |
| Jul 2, 2021 | Advicenne : July 2, 2021 - Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA | Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA Paris, France, 2nd July 2021 - 7 am CEST - Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commer... |
| Jul 2, 2021 | Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA | Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA Paris, France, 2nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commer... |
| Jun 22, 2021 | Advicenne : June 21, 2021 - Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m | The following pages contain information regarding the share capital increase of Advicenne. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access s... |
| Jun 22, 2021 | Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10 million | Regulatory News: Advicenne SA (FR0013296746 - ADVIC) (the “Company”), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announced today the lau... |
Show more
Reviews 0
FAQ about ADVICENNE
How much funding has ADVICENNE raised?
ADVICENNE has raised $29.07M in total across 2 funding rounds.
What funding rounds has ADVICENNE raised?
Parsers VC lists 2 funding rounds of ADVICENNE, among them a funding round of $17.18M on Mar 20, 2017.
Who has invested in ADVICENNE?
Parsers VC lists 2 investors of ADVICENNE, among them Crealia.
What has the press written about ADVICENNE?
Parsers VC has collected 18 articles mentioning ADVICENNE, among them “Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA” (Dec 20, 2021) and “Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA” (Dec 20, 2021).
Is ADVICENNE still active?
Yes, ADVICENNE is active; its latest activity on Parsers VC dates from Jan 4, 2022.